Lombard Medical announces 2006 Results


Lombard Medical announces 2006 Results (pdf)



Date   

Title

3/10/2010 1:25:00 PM
International Congress (XXIII) Endovascular Interventions
2/5/2010 3:19:00 PM
Share Option Grant
2/2/2010 5:27:00 PM
Total Voting Rights
2/1/2010 1:16:00 PM
Result of General Meeting
1/29/2010 10:40:00 AM
Result of offer to qualifying shareholders and qualifying employees
1/13/2010 4:25:00 PM
Issue of equity to raise £13 million
12/24/2009 11:22:00 AM
Change of Nominated Adviser and Broker
11/17/2009 10:59:00 AM
Disposal of Polymer Coatings Business to Bayer
10/12/2009 10:03:00 AM
John B. Rush appointed CEO at Lombard Medical
9/23/2009 12:55:00 PM
Further Positive Aorfix™ Data Reported at CIRSE and TCT
9/11/2009 2:04:00 PM
2009 Oxford and South East Bioscience Award for Best Medtech Fundraising
9/2/2009 10:51:00 AM
FDA acceptance of the first of six modules of PMA filing for Aorfix™
8/7/2009 1:06:00 PM
Interim results for the six months ended 30 June 2009
6/18/2009 1:24:00 PM
Report and Accounts
6/4/2009 1:08:00 PM
European Label Claim Extension for Aorfix™ to Treat Patients with High-angle-neck Aneurysms
5/20/2009 11:48:00 AM
AGM Trading Update
5/20/2009 11:45:00 AM
AGM May 2009 Results
4/6/2009 10:58:00 AM
Positive Aorfix™ Data in Challenging Anatomies Reported at Charing Cross Symposium
4/1/2009 10:58:00 AM
Preliminary Results for year ended 31 December 2008
3/12/2009 4:34:00 PM
Lombard Medical Regains Marketing Rights for EndoRefix™
2/27/2009 12:38:00 PM
NICE Guidelines for the Treatment of Abdominal Aortic Aneurysms
1/29/2009 2:19:00 PM
Share Option Grant
1/13/2009 2:56:00 PM
Employee Consultation regarding Redundancies
1/12/2009 1:16:00 PM
Fundraising Circular
1/9/2009 11:40:00 AM
Placing and Subscription to raise £6.1 million
12/10/2008 11:09:00 AM
EndoRefix™ Trial Suspended
11/26/2008 10:40:00 AM
Growing positive experience of Aorfix™ across the world - Approval received for Aorfix™ in Russia
11/24/2008 4:19:00 PM
US Trial and Further Cost Cutting Measures
10/17/2008 5:06:00 PM
Update
9/26/2008 10:46:00 AM
£1.6 million fundraising
9/22/2008 11:22:00 AM
European Arbiter II Trial Completes Recruitment
8/15/2008 6:14:00 PM
Interim Results for the six months ended June 2008
5/12/2008 12:10:00 PM
AGM Trading Update
4/30/2008 11:22:00 AM
US EndoRefix™ Pivotal Trial commences
4/16/2008 12:16:00 PM
FDA Acceptance for Aorfix™ as a Modular PMA and Successful Charing Cross Symposium
3/20/2008 11:27:00 AM
Preliminary Results for Year ended 31 December 2007
1/16/2008 11:29:00 AM
Lombard Directors' Share Purchase
1/14/2008 12:38:00 PM
Result of Lombard EGM and Company Strategy Update
1/8/2008 3:00:00 PM
NHS screening programme for treatment of AAA
12/20/2007 10:22:00 AM
Fundraising of £7.6 million
11/19/2007 11:15:00 AM
Aorfix™ successfully passes 21- patient case review by FDA
10/22/2007 12:31:00 PM
CE Mark and conditional IDE approval received for second-generation EndoRefix™
9/20/2007 11:34:00 AM
Lombard Medical Announces board changes
9/20/2007 11:23:00 AM
Lombard Medical Announces interim results 2007
7/30/2007 11:12:00 AM
Lombard Medical Receives Full FDA Approval of its Supplemental IDE to Pivotal US Clinical Trial
7/13/2007 10:19:00 AM
First US Case in a Patient with a High Angle Neck Aneurysm using Gen II Aorfix™
7/5/2007 3:27:00 PM
Lombard Medical enters into Collaboration with Smith & Nephew to Develop Bioresorbable Drug-eluting Coronary Stents
6/20/2007 1:42:00 PM
Lombard Medical Announces the Acquisition of Culzean Medical Devices Limited
6/15/2007 12:51:00 PM
Lombard Medical Placing announcement
6/15/2007 12:34:00 PM
Lombard Medical announces 2006 Results
5/31/2007 11:52:00 AM
Lombard Medical Receives Conditional FDA Approval of its Supplemental IDE to Pivotal US Clinical Trial
5/22/2007 12:23:00 PM
First Cases for Aorfix™ in Brazil
4/23/2007 6:35:00 PM
Lombard Medical Announces Filing of Supplemental IDE to Pivotal US Clinical Trial for Aorfix™ and Provides Progress Update
4/4/2007 1:24:00 PM
Lombard Medical receives FDA approval of its Supplemental IDE to use "Gen II" Aorfix™ in Pivotal US Clinical Trial
2/23/2007 11:06:00 AM
Trade Investment in Endoart SA
2/12/2007 12:27:00 PM
Yorkshire Forward Grant for Development of Urinary Catheters
2/5/2007 12:22:00 PM
Successful Clinical Cases
1/30/2007 12:00:00 PM
Recommencement of European Clinical Procedures For Second Generation Stent Graft
1/9/2007 1:52:00 PM
Board Change
12/14/2006 10:18:00 AM
Lombard Medical Announces Strategic Collaboration for its Refix™ Endostapler
12/11/2006 5:00:00 PM
Lombard Medical Technologies PLC Total Voting Rights and Share Capital
12/11/2006 4:47:00 PM
Temporary Suspension of European Clinical Procedures For Second Generation Stent Graft
11/10/2006 12:04:00 PM
Lombard Medical announces receipt of CE Mark for its Refix™ Endostapler
11/8/2006 2:23:00 PM
Lombard Medical receives conditional FDA approval of its supplemental IDE for Aorfix™
10/2/2006 12:59:00 PM
Lombard Technologies PLC announces a Collaboration for the Development of a Next Generation Regenerative Stent
9/11/2006 10:32:00 AM
Positive 24 month Clinical Data for Aorfix™ Stent Graft
8/25/2006 10:42:00 AM
Lombard Medical Technologies PLC Trading Update
8/25/2006 10:15:00 AM
Lombard Medical Technologies PLC retains distribution rights for Aorfix™, AAA and Thoracic Stent Grafts
8/3/2006 1:27:00 PM
Lombard Medical enters into collaboration with Axordia for stem cell derived drug eluting stents
5/10/2006 10:31:00 AM
Annual General Meeting
4/13/2006 3:30:00 PM
Positive 12 month Clinical Data for Aorfix™ Stent Graft
4/4/2006 5:07:00 PM
Research Agreement with Amgen and University of Sheffield
3/24/2006 4:44:00 PM
Company Completes Successful Year
2/24/2006 10:59:00 AM
CE Mark and conditional IDE approval received for second-generation EndoRefix™
2/17/2006 2:25:00 PM
Lombard Medical receives full IDE approval for its US clinical trial of its Aorfix™ stent graft
2/15/2006 9:22:00 PM
Application for admission of ordinary shares
2/10/2006 9:18:00 PM
Lombard Medical Announces that Abdominal Aortic Aneurysm Screening to Commence in the US
1/19/2006 2:41:00 PM
Lombard Medical reports new data demonstrating that its Aorfix™ stent graft reduces the risk of endoleaks in angulated necks
1/19/2006 2:16:00 PM
Directors share purchase
1/17/2006 3:43:00 PM
Application for admission of ordinary shares
12/13/2005 3:46:00 PM
Lombard Medical Technologies PLC commences trading on AIM
12/7/2005 9:08:00 PM
Lombard Medical Technologies PLC raises £26.2 million on successful completion of IPO